The answer has nothing to do with how promising a drug is clinically, and everything to do with its chemistry. A molecule's size, its functional groups, and how many solid-state forms it can crystallize into: these are the parameters that determine how exposed a compound is to patent claiming, and how much room is left for the next company to file something new.
Here's the real question: if you picked a psychedelic molecule today, how much room is there to stake a new, defensible claim on it? We ranked the seven compounds investors ask about most, from the most exposed to the most locked down. It runs from LSD, where the molecule is huge and only one company has claimed a salt of the parent compound itself, down to MDMA, where the standard salt is decades old, the one attempt to patent a formulation around it was rejected, and what protection exists has moved onto processes and isotopes.
There are two very different ways a claim can end up "closed." Sometimes it's closed because one company already owns it. Sometimes it's closed because the chemistry won't offer new opportunities. Both end in "no room left." Two further patterns run across compounds regardless of their native chemistry: deuteration, replacing specific hydrogen atoms with deuterium, a heavier hydrogen isotope, to create a chemically distinct, separately patentable compound; and stereochemistry, isolating one mirror-image form of a chiral molecule, which turns out to matter on both ketamine and MDMA.
1. LSD: The Biggest Molecule, and the Salt Space Nobody's Claimed Yet
LSD is by far the largest and most structurally complex molecule in this group: an ergoline scaffold with a diethylamide arm and multiple stereocenters. Bigger and more complex generally means more places to modify it: you can swap out the diethylamide for a different amide, substitute the indole nitrogen, and because the molecule is chiral, you get enantiomer and diastereomer options that are absent in simpler tryptamines like DMT and psilocybin.
The original LSD patents, filed by Sandoz back in 1943, expired more than half a century ago, so the molecule itself is public domain. Nobody can claim LSD as such anymore. What's left to claim has to be salts, new derivatives or analogs: a molecule different enough from LSD to count as its own invention. Definium Therapeutics (formerly known as MindMed) holds lysergide D-tartrate, the salt that actually matters commercially right now, the form behind its lead candidate DT120 (formerly MM120). The patent identifies this specific salt by its XRPD (X-Ray Powder Diffraction) signature, essentially a chemical fingerprint. Definium also holds a separate patent on DT120's tablet formulation itself, protection running to 2041, on top of the underlying salt patent. DT120 received FDA Breakthrough Therapy designation for generalized anxiety disorder back in 2024, and in June 2026 it reported positive Phase 3 topline results in major depressive disorder as well.
The salt space itself is also less empty than a single granted patent suggests. Sandoz's original 1947 Delysid was itself a tartrate salt, so tartrate broadly is old prior art; what Definium's granted patent actually protects is the D-tartrate enantiomer in one specific, defined crystal form. Separately, Definium (again under the Mind Medicine name) has a pending application, "LSD Salt Crystal Forms," that claims a long list of additional counterions, hydrobromide, citrate, phosphate, fumarate, sulfate, mesylate, acetate, oxalate, benzoate, and more, plus free-base polymorphs generally. Nothing here is granted yet, and no other filer appears to have run a salt-screening campaign on LSD, but it means Definium is trying to claim much of the remaining salt space too.
On the new-molecule side, a couple of companies are actually designing LSD analogues. Delix Therapeutics, co-founded by UC Davis's David Olson (watch our recent live interview with David Olson here), holds an exclusive license to JRT, an LSD analogue built by swapping just two atoms in the ring system to strip out most of the hallucinogenic effect while keeping the neuroplastic property. Seaport Therapeutics has a 2-bromo-LSD program in the pipeline too. Both are novel compositions of matter rather than reformulations, which is the strongest kind of patent claim available.
On deuteration: Definium is the one to watch here too. Alongside the D-tartrate salt, the company has a pending application covering a broad range of fluorinated and deuterated LSD derivatives, structured as several compound classes spanning multiple positions on the molecule. It's not a granted patent yet, and it's unclear how much of that scope will survive prosecution.
LSD comes out on top because Definium's only granted claim on the parent molecule is the one D-tartrate enantiomer salt, leaving genuinely open territory for now, though its own pending applications, covering both a broad range of other salts and a broad range of fluorinated and deuterated derivatives, mean that territory is narrowing faster than the granted patents alone would suggest.
2. Psilocybin: The Salt Route Nobody Thought Existed
Psilocybin's structure is friendly to patent claimants for one specific reason: it has a phosphate ester hanging off the indole ring. The phosphate sits deprotonated while the dimethylamine sits protonated, so the two neutralize each other inside the molecule. That internal balance, which makes psilocybin a zwitterion, gives it a stable crystal lattice without needing any external counterion at all. Those crystals can pack into multiple different lattice structures, called polymorphs, each with its own fingerprint under x-ray diffraction (XRPD). Each new, genuinely distinct polymorph is, in principle, its own separate patent opportunity. The same internal balance was long assumed to rule salts out entirely, since there appeared to be no free charge left for an acid to pair with, which is why this molecule's patent history runs through crystal forms rather than salts. When Terran discovered that psilocybin could form salts in 2023, that changed the whole game.
Compass Pathways built its whole IP position on what was then thought to be the only workable solid form: the free-base crystal. Their foundational patent claims a specific crystalline form of the psilocybin free base (the neutral, naturally-occurring zwitterion, not a salt) that they call Polymorph A, characterized by specific XRPD peaks, along with the synthesis process and treatment protocols. The scientific literature describes three known crystal forms of zwitterionic psilocybin, Form A, Form B, and Form A-Prime, and industry commentary describes Compass as holding patents across all three, though we've only independently confirmed the claims specifically challenged and upheld, which covered Polymorph A. COMP360, Compass's clinical asset, is built on Polymorph A specifically, not a hydrochloride salt. When the nonprofit Freedom to Operate tried to get those claims invalidated at the USPTO, the board denied the challenge but read them narrowly: Compass owns that exact crystalline shape, not psilocybin crystals in general. So there's real room left, for other polymorphs, and for the salt forms Compass never made.
Several doors are open here. First, undiscovered polymorphs of the free base itself, since crystallography is trial and error rather than something you can exhaustively map. Second, and more consequentially: Terran Biosciences showed in 2023 that the zwitterion actually can form salts after all, contrary to the old assumption, and patented psilocybin hydrochloride and edisylate forms as a result. Because these are chemically distinct entities from Compass's free-base polymorphs, an acid salt versus a neutral crystal, they don't infringe Compass's claims. Third, the metabolite route: psilocybin is itself a natural prodrug — the body converts it into psilocin, the actual active compound — and psilocin's own salt and crystal forms are separately patentable. Lobe Sciences (through its subsidiary Cynaptec) holds a patented psilocin mucate salt, branded Conjugated Psilocin. CaaMTech has taken a related but distinct approach, engineering its own synthetic prodrugs designed to convert into psilocin, including CT-4201, cleared by the FDA for clinical development for major depressive disorder. Fourth, deuteration: Lennham Pharmaceuticals holds a broad patent (expiring 2040, priority date October 2020) covering deuterated forms of both psilocybin and psilocin under a wide genus claim, allowing anywhere from a single deuterium substitution up to full replacement across several distinct sub-formulas. A related Lennham filing goes further, extending the same claim beyond deuterium to carbon-13, nitrogen-15, and oxygen-18 labeling of the same molecule, so this isn't just a deuterated-psilocybin patent; it's an isotope-labeling patent covering psilocybin generally. Helus Pharma (formerly Cybin) has its own deuterated psilocin analogue, HLP003 (d10-psilocin), now in Phase 3 under FDA Breakthrough Therapy designation. There's a smaller fifth option too: halogenation, adding a fluorine at a spot on the molecule that doesn't interfere with 5-HT2A receptor binding. It's a common, low-risk move in pharma chemistry generally, though whether it clears the novelty bar against psilocybin itself hasn't really been tested.
Psilocybin ranks just behind LSD because the opening here is narrower and much better mapped out. Compass has real, tested claims and already survived one challenge, but the narrow reading of Polymorph A, plus the salt route Terran opened up, and the metabolite route several other companies are now working, still leave multiple workable paths in, even with deuteration itself now being claimed.
3. DMT: One Narrow Salt Grant, and Most of the Space Untouched
DMT is the simplest tryptamine in this whole group, it is the bare indole-ethylamine core. The free base form is unstable: low melting point, short shelf life, which is why all the patent activity has gone toward salts instead of the parent molecule.
Atai holds a granted US patent covering five new DMT salt forms (fumarate, succinate, malate, oxalate, and sulfate), each claimed in a specific crystal packing they call Form A, with its own XRPD signature. The salt is which acid pairs with the molecule; the crystal form is how that salt stacks in the solid, and each is separately claimable. The patent was granted in 2025 off a 2021 priority filing. Atai has also been consolidating the space by acquisition in addition to filing: it licensed Psilera's DMT patent portfolio in early 2025. Separately, and unrelated to Atai, Helus Pharma (formerly Cybin) holds HLP004, a deuterated DMT candidate now in Phase 2 for generalized anxiety disorder. Helus Pharma's HLP004 alone closes deuteration's door.
DMT ranks ahead of 5-MeO-DMT because of how little Atai's grant actually covers. DMT is an ordinary basic amine, so it forms salts with essentially any pharmaceutically acceptable acid, and the standard screening list runs to dozens of counterions. Five is a slice of that, not a wall around it. Only deuteration is genuinely shut, and that is Helus, not Atai. The analog space is emptier still, with no serious occupancy on the substituted tryptamines around it.
4. 5-MeO-DMT: Open Chemistry, Closing Fast
5-MeO-DMT is simpler than psilocybin. Where psilocybin carries a phosphate group, 5-MeO-DMT has a methoxy group, which is chemically inert. It sits on the molecule and does nothing. That leaves the nitrogen free to grab an acid, so 5-MeO-DMT forms salts easily, the way most amines do. There's no chemical obstacle here.
So why has the patent activity gone to sprays, inhalers, and infusions rather than salts? Two reasons. The free base is an oil, so anyone who wants a solid they can weigh and put in a capsule needs a salt just to get started. And more importantly, 5-MeO-DMT hits within seconds and is finished inside half an hour. At that speed, how fast the drug reaches the brain isn't a detail of delivery. It is the treatment. An inhaled dose, a nasal spray, and an IV infusion give three different concentration curves, and in practice three different clinical products. Delivery isn't the consolation prize here for companies who found the chemistry taken. It's where the invention actually is.
GH Research holds the most established claim on the molecule: a European patent (EP3927337), granted by the EPO in January 2024 and not expiring before 2040, covering 5-MeO-DMT (which they call mebufotenin) and its salts broadly, across inhaled, intranasal, buccal, sublingual, IV, and IM routes, for major and treatment-resistant depression. That specific patent is a use-and-route claim, not ownership of the free base itself. 5-MeO-DMT is a naturally occurring compound, found in certain toad secretions and plants and known in the chemical literature since the 1930s, so the molecule itself is old prior art nobody can own. That doesn't mean GH Research has no composition-of-matter protection at all, though: among their 25-plus additional applications are new salt forms, crystalline polymorphs, and aerosol formulations, genuine composition claims on specific new things they've invented, layered on top of the broader use claim, alongside new manufacturing methods and delivery devices.
This space just got a lot more contested. On July 16, 2026, Eli Lilly announced it is acquiring AtaiBeckley for up to $3.8 billion, largely for BPL-003, a mebufotenin benzoate nasal spray advancing into Phase 3 for treatment-resistant depression, alongside VLS-01, a DMT buccal film. Beckley Psytech's own 5-MeO-DMT benzoate salt patent is now part of that estate. GH Research and AtaiBeckley are in an active dispute over overlapping mebufotenin claims (the "mebufotenin melee" reported by Psychedelic Alpha).
Deuteration doesn't offer a way around either of them regardless: Helus Pharma already holds a patent on deuterated 5-MeO-DMT crystalline forms, through its 2023 acquisition of Small Pharma, so a third, independent estate already sits on that specific option too.
5-MeO-DMT ranks below DMT because the field just went from one aggressive filer to three separate estates (GH Research, Lilly-backed AtaiBeckley, Helus Pharma on the deuterated side), and two of them are contesting the same ground rather than dividing it. There's still room around the edges: new salt forms, new delivery formats nobody's claimed yet.
5. Ibogaine: The Real Prize Is the Metabolite
Ibogaine is a different animal from the tryptamines above, a much bigger, more complex indole alkaloid, and so its patent story developed differently. The parent compound is a natural product that's been public domain forever, and its acute cardiac risk (it can prolong the QT interval) has pushed most Western drug development away from ibogaine itself and toward its main active metabolite, noribogaine, which lacks the QT-prolongation effect.
DemeRx, founded by Deborah Mash, holds by far the biggest ibogaine-related patent estate out there: uses of ibogaine and noribogaine for opioid and alcohol use disorder, methods for boosting an opioid painkiller's effect without extending QT interval, and its own formulations pairing noribogaine with other iboga alkaloids like voacangine or coronaridine (watch our recent live interview with Deborah Mash here). Their noribogaine candidate, DMX-1001, got FDA IND clearance in April 2026, the first ibogaine-related program cleared by the FDA for US clinical trials, with Phase 2 for alcohol use disorder expected in 2027. A related compound, DMX-1002 (ibogaine HCl itself, aimed at opioid use disorder), ran for several years under a joint venture between DemeRx and Atai, but has gone quiet on Atai's pipeline since a QTc safety signal turned up in its Phase 1 data, effectively leaving DemeRx to take DMX-1001 forward independently.
Deuteration is the one door on this list we could not find claimed by anyone: no deuterated ibogaine or noribogaine patent appears in the published record. That's a weaker statement than the others in this piece. Applications stay confidential for eighteen months after filing, so an unpublished claim could already exist.
A new filer needs something DemeRx's claims don't already sweep in: a genuinely novel combination, a new indication, or deuteration, if it is indeed open. The most obvious candidate for a novel combination is pairing ibogaine with magnesium to offset its cardiac risk, and that turns out to be claimed too, just by a different party than DemeRx. Magnesium co-administration is intended to blunt the arrhythmia risk that has kept ibogaine out of Western clinics. A Stanford team led by Nolan Williams at the Brain Stimulation Lab ran a prospective observational study in 30 male Special Operations veterans with mostly mild traumatic brain injury, giving ibogaine alongside magnesium. They called the protocol MISTIC, published the results in Nature Medicine in early 2024, and disclosed two pending patent applications tied to it.
Ibogaine ranks fifth because the routes that matter here are held rather than absent. The parent alkaloid was never ownable, the metabolite that solves its clinical problem belongs to DemeRx, and the most obvious way to make the parent usable, pairing it with magnesium, was filed on by someone else while the field was watching a different molecule. What remains is real but narrow: a new indication, a combination nobody has tried, and possibly deuteration.
6. Ketamine: Nobody Owns the Molecule, and It's Still the Most Locked Down on This List
Ketamine is the odd one out here because its patent story has nothing to do with salts or polymorphs and everything to do with stereochemistry, which molecular "mirror image" (enantiomer) is being used. Racemic ketamine, the 50/50 mix of the two mirror-image forms (R and S), has been off-patent and generic for decades.
Here is the part that surprises people: esketamine, the isolated S version, is off-patent too. It's the more potent enantiomer at the NMDA receptor, roughly three to four times the affinity, but it was described in the patent literature in 1971 and has been sold in Europe as an anaesthetic under the name Ketanest S since long before anyone thought of using it for depression. The enantiomer is old prior art. Janssen owns no composition claim on it, and in some jurisdictions that also limits what secondary protection around Spravato can be extended.
So what does Janssen actually own? The route, the formulation, and the protocol. Their Orange Book position is seven US patents, sixty-two family members across twenty-four countries, covering intranasal administration of esketamine for depression, the specific nasal spray composition, and dosing regimens. One of those patents is titled intranasal administration of ketamine to treat depression. There is one Paragraph IV challenge on file, and the earliest date a generic could enter the US market is January 17, 2028, though that could push later, into the mid-2030s by some estimates, depending on which method-of-use patents survive litigation. Arketamine, the R version, hasn't panned out commercially; Perception Neuroscience's PCN-101 missed its Phase 2a primary endpoint for treatment-resistant depression.
A deuterated form claim exists, and it belongs to Amorsa Therapeutics. Amorsa holds patents on deuterated ketamine and deuterated norketamine (ketamine's own active metabolite), with a portfolio running to 2035. Whether that's fully independent of Janssen is genuinely unclear: Amorsa signed a research, option, and license agreement with Janssen back in 2017, giving Janssen a worldwide exclusive option on one of Amorsa's preclinical candidates, though it isn't public which candidate, whether it covers the deuterated compounds specifically, or whether the option is still live. Either way, ketamine's isotope door isn't open to a new filer: it's held by Amorsa outright, and possibly by Janssen as well.
Ketamine sits near the bottom, then, for a reason worth stating carefully. Nobody owns the molecule and nobody owns the enantiomer that matters. What Janssen owns is the only FDA-approved way to deliver it for depression, backed by regulatory exclusivity and a litigation posture, and that is functionally a lock even though it isn't molecular ownership. This is the same architecture as Compass on psilocybin and Otsuka on methylone, just further along: public-domain chemistry, protection assembled entirely from method, formulation, and regulatory position, which is what this pattern looks like once a drug actually reaches the market.
7. MDMA: Tried To Patent It, and Lost, Though Not on Every Front
MDMA is a different chemical class entirely from everything else here: a substituted amphetamine rather than a tryptamine, an ergoline, or an alkaloid. MDMA forms salts easily; the hydrochloride has been the standard form of the drug since Shulgin-era work in the 1970s. So this isn't a case of the molecule resisting salt chemistry. It's the opposite problem. MDMA is an ordinary amine, salt formation on it is trivial, and the space got mapped decades ago by people who weren't trying to own anything. There was never a mistaken assumption here for someone to overturn the way Terran overturned the zwitterion assumption on psilocybin. The salt everyone uses is old, well-characterized prior art with nothing novel left in it. And the molecule itself goes back to Merck in 1912, synthesized as an intermediate long before anyone proposed a therapeutic use, so a straight ownership claim was never on the table for anyone.
MAPS built its whole strategy on the opposite bet: keep MDMA unpatented on purpose, publish everything openly, and win on data and first-mover advantage instead of a patent wall. That changed between 2022 and 2023, when Lykos Therapeutics, the public benefit corporation MAPS spun out to run the regulatory filing, quietly filed a batch of applications covering specific forms and formulations, most notably a composition defined by a narrow particle size range for milled MDMA hydrochloride. That reversal drew real criticism given MAPS's decades of publicly anti-patent positioning. It didn't work: by March 2026, the USPTO had rejected all of Lykos's particle-size claims as obvious, in light of a prior Awakn Life Sciences patent application on MDMA for alcohol use disorder that the examiner found covered the same ground. So Lykos, and anyone else trying to patent MDMA's salts or formulations, is left without a real moat.
Two other routes have gone differently. The first is stereochemistry. MDMA has a chiral center, giving an S enantiomer whose effects run through dopaminergic and noradrenergic pathways and resemble a psychostimulant, and an R enantiomer that works serotonergically, including direct 5-HT2A agonism, with preclinical evidence pointing to a higher therapeutic index. Neither enantiomer is ownable as a compound, since both were described in Nichols and Shulgin's work in the 1980s. But PharmAla Biotech was granted US Patent 12,679,817 in August 2026 covering novel enantioselective processes for preparing the R and S forms of MDMA and MBDB, and separate applications are pending on non-racemic mixtures with R-MDMA in enantiomeric excess, pitched as balancing the two enantiomers to reduce the toxicity associated with S-MDMA, and on R(−)-MDMA for anxiety disorders including social anxiety. This is the ketamine pattern arriving on MDMA: the enantiomer is public, so the claims attach to how you make it, what ratio you use it in, and what you treat with it.
The second is deuteration. A granted patent, "Deuterated Empathogens" (filed 2021-2022, claiming deuterated analogues of MDMA and the related compound methylone), shows the isotope route produces something genuinely patentable, where the salt and formulation routes ran into old prior art and obviousness rejections instead. The holder is the Alexander Shulgin Research Institute, which licenses its portfolio commercially, including a 2024 deal with Negev Labs. So the door is claimed by an organization with a real commercial incentive around it, whatever the name suggests.
ASRI's patent covers deuterated versions of MDMA and methylone, and it's worth separating that from what's actually reaching the clinic. The successor compounds in development are ordinary, non-deuterated molecules, and none of them is patentable as a composition either. Methylone (TSND-201), MBDB, and MDEA all come out of Shulgin-era phenethylamine and cathinone chemistry, which is exactly what puts them in the public domain; methylone's own composition patent lapsed years ago. So developing a successor compound is not a way of obtaining composition-of-matter protection, and deals in this space are made of something else.
Which makes Otsuka's March 2026 acquisition of Transcend Therapeutics, TSND-201's developer, for up to $1.225 billion, the most instructive transaction in this piece. What Otsuka bought was Phase 2 IMPACT-1 data published in JAMA Psychiatry, a Breakthrough Therapy designation, an FDA Commissioner's National Priority Voucher, a mechanism that doesn't run through 5-HT2A and therefore doesn't require supervised dosing sessions, and a set of follow-on prodrugs that genuinely are novel compositions. The protection is NCE regulatory exclusivity plus Orange Book method and formulation patents. A real position, and a thinner and shorter one than a molecule patent (read our Current pieces on the successor compounds of MDMA here and here).
MDMA ranks dead last because it is the one compound here where a claiming route was tested and refused rather than merely occupied. Lykos tried salts and formulations; the examiner rejected them. Two routes did produce grants, though: ASRI holds the deuterated forms, and PharmAla holds process claims on the enantiomers. Neither is composition of matter on the molecule, which nobody can have. What's left on MDMA is the same architecture as ketamine, one step earlier: the chemistry is public, and any position built here will be made of process, formulation, method, and regulatory exclusivity rather than ownership of the compound.
What this means for diligence
These seven compounds really break into three different situations, and "hard to patent" means something different in each one.
Open chemistry, low occupancy: LSD, psilocybin, and DMT still have real, findable white space, either because the scaffold can support more modifications than anyone's filed on yet, or because no single company has consolidated the field. This is where a new entrant has the best odds of walking away with something defensible.
Open chemistry, closing fast: 5-MeO-DMT still has room, but three well-funded players, GH Research, Lilly-backed AtaiBeckley, and Helus Pharma on the deuterated side, are now holding ground on the same molecule. Diligence here means tracking which salts and which XRPD patterns are already claimed, and watching how the reported GH Research/AtaiBeckley dispute plays out.
Closed, either by an owner or by the chemistry itself: ibogaine, ketamine, and MDMA are all effectively locked, but not for the same reason, and ketamine's reason is the one most often misread. Nobody owns the ketamine molecule, and nobody owns the esketamine enantiomer either. What Janssen holds is the intranasal route, the nasal spray formulation, the dosing protocols, and the regulatory position behind them, which is functionally as tight as ownership without being ownership. Ibogaine is closer to a true owner lock, with DemeRx holding the metabolite that solves the compound's actual clinical problem, and Amorsa holds ketamine's isotope side outright. MDMA is the only case here where a route was tested and refused rather than merely taken: the USPTO rejected Lykos's salt and formulation claims outright. Its other routes are occupied rather than closed, with ASRI on the deuterated forms and PharmAla on the enantiomer processes.
One pattern cuts across all three buckets rather than sitting inside any single one: deuteration. It's already claimed on psilocybin, DMT, 5-MeO-DMT, ketamine, and MDMA, each by a different company, and on the granted record it is unclaimed on LSD and ibogaine. Those two open doors are not equally open. Definium has a pending application covering deuterated and fluorinated LSD derivatives, so LSD's isotope route is open today rather than open indefinitely. Ibogaine's simply returned nothing, which is a weaker finding, since applications stay confidential for eighteen months after filing. Because deuteration doesn't depend on a molecule's native chemistry the way salts and polymorphs do, it's worth checking as its own line item on any asset.
One more layer worth flagging, and one we've only partially confirmed: not every "deuterated" patent claims the same scope. Lennham's psilocybin patent explicitly claims deuterium and carbon-13, nitrogen-15, and oxygen-18 labeling under one genus, so the whole isotope-labeling strategy is spoken for on that molecule, not just the deuterium version. The DMT and MDMA deuteration patents we could read, by contrast, appear to claim deuterium specifically rather than isotopes generally, which would leave a carbon-13 or nitrogen-15 version of either molecule as a real, if narrow, unclaimed door. We weren't able to confirm the exact claim scope for the 5-MeO-DMT and ketamine deuteration patents in the time available. The practical takeaway: "deuterated" alone doesn't tell you how wide a given patent's door actually is, that requires reading the specific claim language, not just noting that deuteration has been filed on.
So the real question for any new psychedelic asset was never just "how novel is this compound." It's which situation a given filing actually sits in: is there real chemical white space left, is that space actively closing under one or more aggressive filers, or has the ground already been taken. And where it has been taken, by what. A competitor's estate and the molecule's own prior art both leave you with nothing to claim, but only one of them can be designed around, licensed, or challenged. On ketamine and MDMA the answer is neither, exactly: the chemistry is public and the position that matters is built from process, method, formulation, and regulatory exclusivity, which is a different thing to diligence and a different thing to compete with.
Written by Alexandre Stipanovich, with AI-assisted research, fact-checking, and editing (Claude Sonnet & Opus 5).
This piece is for informational purposes and does not constitute legal advice on patent validity or freedom-to-operate. Readers evaluating a specific asset should consult qualified patent counsel.